Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fp/ABS · 1 trial · 1 indication
Baseline values are averaged on day 1 to get a single value. Area under the effect curve will be calculated using measurements collected between zero and 6 hours after dosing. Baseline-adjusted post-dose FEV1 AUEC0-6h for visits on Day 1 and at Week 4 will be calculated using the trapezoidal rule.
| Arm | Type | Description |
|---|---|---|
| Fp/ABS eMDPI | EXPERIMENTAL | Fluticasone propionate/albuterol sulfate multidose dry powder inhaler with electronic module |
| Fp eMDPI | ACTIVE_COMPARATOR | Fluticasone propionate (Fp) dry powder inhaler with an integrated electronic module (eMDPI) |
| ABS eMDPI | ACTIVE_COMPARATOR | Albuterol sulfate (ABS) dry powder inhaler with an integrated electronic module (eMDPI) |
| Placebo eMDPI | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Fp/ABS | DRUG | Inhalation powder |
| FP | DRUG | Inhalation powder |
| ABS | DRUG | Inhalation powder |
| Placebo | DRUG | Inhalation powder |
Inclusion Criteria: * The participant has a diagnosis of asthma of at least 6 months duration. * Participants currently receive a beta-agonist (eg, salbutamol \[albuterol\] or ICS albuterol or ICS-formoterol) as rescue medication with or without asthma controller medication. * If female, a particip...
Fp/ABS is an investigational small molecule being developed for the treatment of asthma. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients 12 years and older with asthma.
Fp/ABS is a combination of fluticasone propionate and albuterol sulfate. Fluticasone propionate is a corticosteroid that reduces inflammation in the airways, while albuterol sulfate is a bronchodilator that relaxes muscles in the airways to improve breathing. The combination is designed to address both inflammation and bronchoconstriction in asthma.
Fp/ABS is being developed by Teva Pharmaceutical Industries Limited, a company traded on the stock exchange under the ticker symbol TEVA. Teva is conducting clinical trials to evaluate the safety and efficacy of this drug candidate for the treatment of asthma.
Fp/ABS is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 3 trial is designed to assess the efficacy and safety of the drug in patients with asthma.
Fp/ABS is being evaluated in a Phase 3 clinical trial registered as NCT06664619. This is a randomized, double-blind, placebo-controlled study with an enrollment of 724 participants aged 12 years and older with asthma. The trial is currently recruiting and is being conducted in multiple countries including the United States, Argentina, Bulgaria, Czechia, Germany, Israel, Mexico, Poland, Romania, Slovakia, and Turkey.
Yes, Fp/ABS is the abbreviation for fluticasone propionate and albuterol sulfate combination. This combination therapy is being developed by Teva Pharmaceutical Industries for the treatment of asthma. The drug is currently in Phase 3 clinical trials and has not yet been approved for use.